SCHEMBL659725

SCHEMBL659725

Nc1nc2ccc(F)c(Br)c2s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.44
GFER P55789 1/20 0.44
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
SCN4A P35499 3/20 0.38
EPHX2 P34913 1/20 0.38
SMN1; SMN2 Q16637 6/20 0.37
RAB9A P51151 5/20 0.37
GAA P10253 2/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HSD17B10 Q99714 3/20 0.36
ALOX15 P16050 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
ALOX12 P18054 1/20 0.36
NPC1 O15118 4/20 0.35
LMNA P02545 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17609992 0.81 AXL (0.47) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL8379060 0.81 MAPT (0.45) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL35211614 0.78 SMN1; SMN2 (0.52) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL3136682 0.78 AXL (0.44) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL20855167 0.78 SMN1; SMN2 (0.49) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL1638897 0.78 CCNE1 (0.47) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL19709638 0.78 AXL (0.44) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL19709636 0.78 ALDH1A1 (0.33) ALDH1A1KMT2A
SCHEMBL35212496 0.77 SCN4A (0.45) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL22993546 0.77 ALDH1A1 (0.55) AXLGFERMAPTALDH1A1SCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS INC (US) 2026-05-07 US disclosed
WO-2026090104-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-03-26 US disclosed
WO-2024059524-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-03-21 WO disclosed
EP-4101852-A1 PYRIDOPYRIMIDINONE COMPOUND AND APPLICATION THEREOF Bebetter Med Inc. (CN) 2022-12-14 EP disclosed
US-20220389013-A1 PYRIDOPYRIMIDINONE COMPOUNDS AND APPLICATIONS THEREOF BEBETTER MED INC. (CN) 2022-12-08 US disclosed
CN-112159405-B Pyridopyrimidinone compounds and application thereof 广州必贝特医药技术有限公司 2021-09-14 CN disclosed
CN-112159405-A Pyridopyrimidinone compounds and application thereof 广州必贝特医药技术有限公司 2021-01-01 CN disclosed
US-10597370-B2 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-24 US disclosed
US-20190144403-A1 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-05-16 US disclosed
WO-2017214005-A1 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-12-14 WO disclosed
US-8378104-B2 7-aminofuropyridine derivatives OSI Pharmaceuticals, LLC (US) 2013-02-19 US disclosed
EP-2534156-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI Pharmaceuticals, LLC (US) 2012-12-19 EP disclosed
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2012-02-23 US disclosed
WO-2011100502-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI Pharmaceuticals, LLC (US) 2011-08-18 WO disclosed
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
EP-1328525-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-A]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-23 EP disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed
WO-2001072752-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389013-A1 PYRIDOPYRIMIDINONE COMPOUNDS AND APPLICATIONS THEREOF KRAS, NRAS, HRAS AXL 1663/4885GFER 3863/4885MAPT 4780/4885
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES MAP3K5, STK17A, MAPKAPK5 AXL 2836/4885GFER 4299/4885MAPT 214/4885
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF CTNNB1, CTNNA1, CTNND1 AXL 4796/4885GFER 4066/4885MAPT 4207/4885
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E AXL 4448/4885GFER 4078/4885MAPT 2943/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 AXL 3890/4885GFER 2904/4885MAPT 3309/4885
US-20190144403-A1 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS LIPG, LPL, CEL AXL 2332/4885GFER 2093/4885MAPT 4599/4885
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 AXL 4612/4885GFER 2069/4885MAPT 4667/4885
US-10597370-B2 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors LIPG, LPL, CEL AXL 2332/4885GFER 2093/4885MAPT 4599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.